Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Fecal Microbiota Transplant

FMT · Whole-Microbiome Transfer

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

6 human trials, about 300 studies, >5,000 participants. The written rationale for this grade is still being prepared.

FDA
FDA Approved (Rebyota, Vowst 2023)
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

FMT is a medical procedure that carries a real, documented risk of transmitting infectious organisms from donor to recipient. The FDA issued a 2019 safety alert after a multidrug-resistant ESBL-producing E. coli was transmitted from an unscreened donor to two immunocompromised recipients, one of whom died, and a 2020 alert after enteropathogenic and Shiga-toxin-producing E. coli transmission linked to two further deaths. Rigorous donor screening and pathogen testing are essential and are why FMT belongs in medical settings. Outside recurrent C. difficile infection its use is investigational, and immunocompromised patients face elevated risk. This is not a do-it-yourself practice. Anyone considering FMT for any condition should work with a qualified gastroenterologist or infectious-disease physician, who can weigh candidacy, screening, and whether a clinical trial is appropriate.

Fecal microbiota transplantation transfers stool, and its entire living microbial community, from a screened healthy donor to a recipient. For recurrent Clostridioides difficile infection the evidence is among the strongest in the microbiome field: a 2013 randomized trial was halted early for efficacy, and the first standardized products cleared the FDA (Rebyota in 2022, Vowst in 2023). Outside that single indication, for inflammatory bowel disease, IBS, obesity, and neurological conditions, the evidence is preliminary and investigational, and leading guidelines advise use only within clinical trials. FMT is a medical procedure with a documented safety history, including pathogen transmission that led to a death, and is not a do-it-yourself practice. It is associated with a sobering lesson for the field: how far a single probiotic capsule sits from transferring a whole ecosystem.

The most powerful microbiome intervention known. FDA-approved for recurrent C. difficile.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Prevention of recurrent Clostridioides difficile infection in adults after standard antibiotic treatment (FDA-approved; guideline-endorsed)
  • Ulcerative colitis and other inflammatory bowel disease (investigational; modest RCT signal; guidelines advise trials only)
  • Irritable bowel syndrome (investigational; guidelines recommend against use outside trials)
  • Obesity and metabolic syndrome (research-stage; small trials show transient or no metabolic effect)
  • Neurodevelopmental and other conditions such as autism (early-stage research; evidence preliminary and mixed)

What people get wrong

  • Often saidA probiotic capsule is basically a mild FMT

    ActuallyFMT transfers an entire living microbial ecosystem of thousands of species; a typical probiotic delivers a handful of defined strains. The gulf between them illustrates how limited single-strain supplementation is by comparison, and it is the central reason FMT works for recurrent C. difficile where narrow probiotics do not.

  • Often saidFMT is FDA-approved for gut and metabolic problems generally

    ActuallyThe FDA approvals are narrow. Rebyota (2022) and Vowst (2023) are approved only for prevention of recurrent C. difficile infection in adults after antibiotic treatment, not for IBD, IBS, obesity, or any other condition. The AGA 2024 guideline explicitly recommends against FMT for IBD and IBS outside clinical trials.

  • Often saidFMT is a low-risk natural wellness practice you can do at home

    ActuallyFMT is a medical procedure with a documented safety history. The FDA issued a 2019 alert after a multidrug-resistant ESBL E. coli was transmitted from an unscreened donor to two immunocompromised recipients, one of whom died, and a 2020 alert after EPEC/STEC transmission linked to two further deaths. Rigorous donor screening is essential; this is not a do-it-yourself practice.

  • Often saidThe idea of using stool as medicine is a recent Western invention

    ActuallyThe first written record is fourth-century Chinese: Ge Hong's Zhou Hou Bei Ji Fang described a fecal suspension for severe diarrhea, and Li Shizhen catalogued fecal preparations in 1578. Modern FMT rediscovered, rather than invented, the approach.

Who profits, and who pushes back

  • C. difficile / GI specialists

    Promotes itClinical

    FMT for recurrent C. diff has among the highest cure rates of any microbiome intervention; strong clinical consensus.

  • Microbiome researchers

    Promotes itAcademic

    Study FMT as a probe of causality, what transferring a whole microbiome does, across many conditions.

  • U.S. Food and Drug Administration

    Pushes backRegulatory safety authority

    FDA is informing health care providers and patients of the potential risk of serious or life-threatening infections with the use of fecal microbiota for transplantation, following reports of infections caused by multidrug-resistant organisms, including one death, prompting new donor-screening and stool-testing requirements.

  • American Gastroenterological Association (2024 guideline)

    Pushes backClinical practice guideline body

    The AGA suggests select use of fecal microbiota-based therapies to prevent recurrence in immunocompetent adults with recurrent C. difficile after standard antibiotics, but does not recommend fecal microbiota-based therapies for inflammatory bowel disease or irritable bowel syndrome, advising patients to seek these only through clinical trials.

  • Els van Nood and colleagues (2013 NEJM trial investigators)

    Pushes backTrial authors, Academic Medical Center Amsterdam

    The study was stopped after an interim analysis: resolution of C. difficile infection occurred in 81% of the infusion group after the first infusion, as compared with 31% receiving vancomycin alone and 23% receiving vancomycin with bowel lavage; the authors concluded infusion of donor feces was significantly more effective for recurrent C. difficile infection than the use of vancomycin.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
USA40%
Europe34%
Other26%

Research published from: USA, Europe, Global.

How we got here

Microbiome transfer is ancient and East Asian in origin. In fourth-century China, during the Eastern Jin dynasty, the physician Ge Hong described in his emergency handbook Zhou Hou Bei Ji Fang the use of a human fecal suspension, later remembered as "yellow soup," to treat severe diarrhea and food poisoning. In 1578 the Ming-dynasty scholar Li Shizhen catalogued fresh and fermented fecal preparations in his Ben Cao Gang Mu for fever, poisoning, and abdominal disease. Modern FMT re-emerged in the West only when clinicians faced recurrent C. difficile infection that antibiotics could not clear. A landmark 2013 randomized trial in the Netherlands was stopped early because donor-feces infusion so dramatically outperformed standard therapy. Over the following decade FMT became a research probe of microbiome causality, and beginning in 2022 the FDA approved the first standardized microbiota products, moving the practice from improvised procedure toward regulated medicine.

  1. 4th century CEGe Hong records fecal suspension ("yellow soup") for severe diarrhea in Zhou Hou Bei Ji Fang, Eastern Jin China
  2. 1578Li Shizhen catalogues fecal preparations for fever and abdominal disease in Ben Cao Gang Mu, Ming China
  3. 2013van Nood NEJM randomized trial stopped early: 81% resolution with donor-feces infusion vs 31% vancomycin alone in recurrent C. difficile
  4. 2013-2020sFMT investigated across IBD, IBS, metabolic and neurological conditions; results modest to mixed
  5. 2019FDA safety alert (June 13): ESBL E. coli transmitted from an unscreened donor to two immunocompromised recipients, one death; MDRO screening required
  6. 2020FDA safety alert (March 12): EPEC/STEC transmission in six patients, two STEC-linked deaths; enhanced donor testing added
  7. 2022FDA approves Rebyota (fecal microbiota, live-jslm), the first approved fecal microbiota product, for prevention of recurrent CDI (Nov 30)
  8. 2023FDA approves Vowst (fecal microbiota spores, live-brpk), the first oral fecal microbiota product, for prevention of recurrent CDI (Apr 26)
  9. 2024AGA guideline endorses fecal microbiota-based therapy for most recurrent-CDI patients and recommends against FMT for IBD/IBS outside trials

At a glance

Mechanism
Transfer of donor stool/microbes
Approved for
Recurrent C. difficile
FDA products
Rebyota, Vowst (2023)
Power
The strongest intervention known

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Fecal Microbiota Transplant. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources